Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Dichloroacetate cancer:

Inhibition of COX2 enhances the chemosensitivity of dichloroacetate in cervical cancer cells. Li B et al. Oncotarget. (2017)

Sensitization of breast cancer cells to paclitaxel by dichloroacetate through inhibiting autophagy. Wang M et al. Biochem Biophys Res Commun. (2017)

Dichloroacetate and cancer: new home for an orphan drug? Kankotia S et al. Biochim Biophys Acta. (2014)

Search results

Items: 1 to 20 of 285

1.

Dichloroacetate and Salinomycin Exert a Synergistic Cytotoxic Effect in Colorectal Cancer Cell Lines.

Skeberdytė A, Sarapinienė I, Aleksander-Krasko J, Stankevičius V, Sužiedėlis K, Jarmalaitė S.

Sci Rep. 2018 Dec 10;8(1):17744. doi: 10.1038/s41598-018-35815-4.

PMID:
30531808
2.

Propranolol Promotes Glucose Dependence and Synergizes with Dichloroacetate for Anti-Cancer Activity in HNSCC.

Lucido CT, Miskimins WK, Vermeer PD.

Cancers (Basel). 2018 Nov 30;10(12). pii: E476. doi: 10.3390/cancers10120476.

3.

Sodium Dichloroacetate Pharmacological Effect as Related to Na-K-2Cl Cotransporter Inhibition in Rats.

Stanevičiūtė J, Juknevičienė M, Palubinskienė J, Balnytė I, Valančiūtė A, Vosyliūtė R, Sužiedėlis K, Lesauskaitė V, Stakišaitis D.

Dose Response. 2018 Nov 20;16(4):1559325818811522. doi: 10.1177/1559325818811522. eCollection 2018 Oct-Dec.

4.

Coupling Dichloroacetate Treatment with Curcumin Significantly Enhances Anticancer Potential.

Kan PC, Chang YJ, Chien CS, Su CY, Fang HW.

Anticancer Res. 2018 Nov;38(11):6253-6261. doi: 10.21873/anticanres.12981.

PMID:
30396945
5.

Combined use of arginase and dichloroacetate exhibits anti-proliferative effects in triple negative breast cancer cells.

Verma A, Lam YM, Leung YC, Hu X, Chen X, Cheung E, Tam KY.

J Pharm Pharmacol. 2018 Oct 25. doi: 10.1111/jphp.13033. [Epub ahead of print]

PMID:
30362115
6.
7.

A framework for large-scale metabolome drug profiling links coenzyme A metabolism to the toxicity of anti-cancer drug dichloroacetate.

Dubuis S, Ortmayr K, Zampieri M.

Commun Biol. 2018 Aug 3;1:101. doi: 10.1038/s42003-018-0111-x. eCollection 2018.

8.

Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.

Yang Z, Zhang SL, Hu X, Tam KY.

Eur J Pharmacol. 2018 Nov 5;838:41-52. doi: 10.1016/j.ejphar.2018.09.016. Epub 2018 Sep 10.

PMID:
30213498
9.

Surface-Functionalization of Zr-Fumarate MOF for Selective Cytotoxicity and Immune System Compatibility in Nanoscale Drug Delivery.

Abánades Lázaro I, Haddad S, Rodrigo-Muñoz JM, Marshall RJ, Sastre B, Del Pozo V, Fairen-Jimenez D, Forgan RS.

ACS Appl Mater Interfaces. 2018 Sep 19;10(37):31146-31157. doi: 10.1021/acsami.8b11652. Epub 2018 Sep 5.

PMID:
30136840
10.

Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.

Pracharova J, Novohradsky V, Kostrhunova H, Štarha P, Trávníček Z, Kasparkova J, Brabec V.

Dalton Trans. 2018 Sep 11;47(35):12197-12208. doi: 10.1039/c8dt02236d.

PMID:
30112527
11.
12.

The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance.

Woolbright BL, Choudhary D, Mikhalyuk A, Trammel C, Shanmugam S, Abbott E, Pilbeam CC, Taylor JA 3rd.

Mol Cancer Ther. 2018 Sep;17(9):2004-2012. doi: 10.1158/1535-7163.MCT-18-0063. Epub 2018 Jun 15.

PMID:
29907593
13.

Targeted reversal and phosphorescence lifetime imaging of cancer cell metabolism via a theranostic rhenium(I)-DCA conjugate.

Yang J, Cao Q, Zhang H, Hao L, Zhou D, Gan Z, Li Z, Tong YX, Ji LN, Mao ZW.

Biomaterials. 2018 Sep;176:94-105. doi: 10.1016/j.biomaterials.2018.05.040. Epub 2018 May 25.

PMID:
29870900
14.

18F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy.

Qian Y, Von Eyben R, Liu Y, Chin FT, Miao Z, Apte S, Carter JN, Binkley MS, Pollom EL, Harris JP, Prionas ND, Kissel M, Simmons A, Diehn M, Shultz DB, Brown JM, Maxim PG, Koong AC, Graves EE, Loo BW Jr.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1183-1192. doi: 10.1016/j.ijrobp.2018.03.045. Epub 2018 Apr 18.

PMID:
29859786
15.

Age-Related Changes in Expression and Activity of Human Hepatic Mitochondrial Glutathione Transferase Zeta1.

Zhong G, James MO, Smeltz MG, Jahn SC, Langaee T, Simpson P, Stacpoole PW.

Drug Metab Dispos. 2018 Aug;46(8):1118-1128. doi: 10.1124/dmd.118.081810. Epub 2018 May 31.

PMID:
29853471
16.

Modulation of Immuno-biome during radio-sensitization of tumors by glycolytic inhibitors.

Gupta S, Dwarakanath B.

Curr Med Chem. 2018 May 31. doi: 10.2174/0929867325666180601101145. [Epub ahead of print]

PMID:
29852858
17.

Dichloroacetate enhances the antitumor efficacy of chemotherapeutic agents via inhibiting autophagy in non-small-cell lung cancer.

Lu X, Zhou D, Hou B, Liu QX, Chen Q, Deng XF, Yu ZB, Dai JG, Zheng H.

Cancer Manag Res. 2018 May 16;10:1231-1241. doi: 10.2147/CMAR.S156530. eCollection 2018.

18.

Triple action Pt(iv) derivatives of cisplatin: a new class of potent anticancer agents that overcome resistance.

Petruzzella E, Sirota R, Solazzo I, Gandin V, Gibson D.

Chem Sci. 2018 Apr 24;9(18):4299-4307. doi: 10.1039/c8sc00428e. eCollection 2018 May 14.

19.

Dual-acting antitumor Pt(iv) prodrugs of kiteplatin with dichloroacetate axial ligands.

Savino S, Gandin V, Hoeschele JD, Marzano C, Natile G, Margiotta N.

Dalton Trans. 2018 May 29;47(21):7144-7158. doi: 10.1039/c8dt00686e.

PMID:
29766157
20.

Doxorubicin triggers bioenergetic failure and p53 activation in mouse stem cell-derived cardiomyocytes.

Cunha-Oliveira T, Ferreira LL, Coelho AR, Deus CM, Oliveira PJ.

Toxicol Appl Pharmacol. 2018 Jun 1;348:1-13. doi: 10.1016/j.taap.2018.04.009. Epub 2018 Apr 11.

PMID:
29653124

Supplemental Content

Loading ...
Support Center